Spinal cholinergic and monoamine receptors mediate the antinociceptive effect of morphine microinjected in the periaqueductal gray on the rat tail, but not the feet.
The antinociceptive effects of morphine (5 micrograms) microinjected into the ventrolateral periaqueductal gray were determined using both the tail flick and the foot withdrawal responses to noxious radiant heating in lightly anesthetized rats. Intrathecal injection of appropriate antagonists was used to determine whether the antinociceptive effects of morphine were mediated by alpha 2-noradrenergic, serotonergic, opioid, or cholinergic muscarinic receptors. The increase in the foot withdrawal response latency produced by microinjection of morphine in the ventrolateral periaqueductal gray was reversed by intrathecal injection of the cholinergic muscarinic receptor antagonist atropine, but was not affected by the alpha 2-adrenoceptor antagonist yohimbine, the serotonergic receptor antagonist methysergide, or the opioid receptor antagonist naloxone. In contrast, the increase in the tail flick response latency produced by morphine was reduced by either yohimbine, methysergide or atropine. These results indicate that microinjection of morphine in the ventrolateral periaqueductal gray inhibits nociceptive responses to noxious heating of the tail by activating descending neuronal systems that are different from those that inhibits the nociceptive responses to noxious heating of the feet. More specifically, serotonergic, muscarinic cholinergic and alpha 2-noradrenergic receptors appear to mediate the antinociception produced by morphine using the tail flick test. In contrast, muscarinic cholinergic, but not monoamine receptors appear to mediate the antinociceptive effects of morphine using the foot withdrawal response.
Fang
F
F
Department of Pharmacology, University of Illinois at Chicago 60612, USA.
Proudfit
H K
HK
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D015306:Biogenic Monoamines / Q000378:metabolism; D005260:Female; D005528:Foot / Q000294:innervation*; D007278:Injections, Spinal; D008784:Methysergide / Q000494:pharmacology; D008845:Microinjections; D009020:Morphine / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology; D009619:Nociceptors / Q000187:drug effects*; D010487:Periaqueductal Gray / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011956:Receptors, Cell Surface / Q000502:physiology; D011950:Receptors, Cholinergic / Q000502:physiology; D013116:Spinal Cord / Q000378:metabolism / Q000502:physiology*; D013623:Tail / Q000294:innervation*; D015016:Yohimbine / Q000494:pharmacology
D015306:Biogenic Monoamines; D011956:Receptors, Cell Surface; D011950:Receptors, Cholinergic; D015016:Yohimbine; D009270:Naloxone; D009020:Morphine; D001285:Atropine; D008784:Methysergide